Conditional ablation of glycogen synthase kinase 3Β in postnatal mouse kidney

Laboratory Investigation

Volumn 91, Issue 1, 2011, Pages 85-96

  Ge, Yan ^a   Si, Jin ^a,b   Tian, Li ^a,c   Zhuang, Shougang ^a   Dworkin, Lance D ^a   Gong, Rujun ^a  

^a BROWN UNIVERSITY   (United States)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

conditional knockout; glomerulus; glycogen; glycogen synthase kinase 3 ; kidney; mouse; tubule

Indexed keywords

ALBUMIN; CRE RECOMBINASE; GAMMA GLUTAMYLTRANSFERASE; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FEMALE; GENE DELETION; GENOTYPE; GLOMERULAR STRUCTURE; GLYCOGEN METABOLISM; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY CONCENTRATING CAPACITY; KIDNEY DEVELOPMENT; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; KIDNEY TUBULE; KNOCKOUT MOUSE; LOXP SITE; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PERINATAL DEVELOPMENT; PERINATAL PERIOD; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; TRANSMISSION ELECTRON MICROSCOPY; URINARY EXCRETION;

ALBUMINURIA; ANIMALS; BLOTTING, WESTERN; FEMALE; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; KIDNEY; KIDNEY CONCENTRATING ABILITY; KIDNEY GLOMERULUS; KIDNEY TUBULES; MALE; MICE; MICE, KNOCKOUT; MICROSCOPY, ELECTRON, TRANSMISSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 78650769755     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.142     Document Type: Article

References (43)

1. Ali A, Hoeflich KP, Woodgett JR. Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev 2001;101:2527-2540.
2. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769-776.
3. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003;116:1175-1186.
4. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001;359:1-16.
5. Rayasam GV, Tulasi VK, Sodhi R, et al. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009;156:885-898.
6. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95-102.
7. Lee HC, Tsai JN, Liao PY, et al. Glycogen synthase kinase 3 alpha and 3 beta have distinct functions during cardiogenesis of zebrafish embryo. BMC Dev Biol 2007;7:93.
8. Patel S, Doble BW, MacAulay K, et al. Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol 2008;28:6314-6328.
9. Van Wauwe J, Haefner B. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention. Drug News Perspect 2003;16:557-565.
10. Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000;406:86-90.
11. Haefner B. A model for NF-kappa B regulation by GSK-3 beta. Drug Discov Today 2003;8:1062-1063.
12. Pomerantz JL, Baltimore D. Signal transduction. A cellular rescue team. Nature 2000;406:26-27, 29.
13. Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepa-tocytes. Am J Physiol Gastrointest Liver Physiol 2002;283:G204-G211.
14. Gong R, Rifai A, Ge Y, et al. Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells. J Biol Chem 2008;283:7401-7410.
15. Steinbrecher KA, Wilson III W, Cogswell PC, et al. Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol Cell Biol 2005;25:8444-8455.
16. Gong R, Ge Y, Chen S, et al. Glycogen synthase kinase 3beta: a novel marker and modulator of inflammatory injury in chronic renal allograft disease. Am J Transplant 2008;8:1852-1863.
17. Gong R, Rifai A, Dworkin LD. Activation of PI3K-Akt-GSK3beta pathway mediates hepatocyte growth factor inhibition of RANTES expression in renal tubular epithelial cells. Biochem Biophys Res Commun 2005;330:27-33.
18. Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, et al. CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int 2008;73:684-690.
19. Martinez A, Castro A, Dorronsoro I, et al. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neuro-degeneration, cancer, and inflammation. Med Res Rev 2002;22: 373-384.
20. Hernandez F, Nido JD, Avila J, et al. GSK3 inhibitors and disease. Mini Rev Med Chem 2009;9:1024-1029.
21. Martin M, Rehani K, Jope RS, et al. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005;6:777-784.
22. Woodgett JR, Ohashi PS. GSK3: an in-Toll-erant protein kinase? Nat Immunol 2005;6:751-752.
23. Dugo L, Collin M, Thiemermann C. Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock 2007;27:113-123.
24. Demarchi F, Bertoli C, Sandy P, et al. Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem 2003;278: 39583-39590.
25. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004;3:479-487.
26. Kuure S, Popsueva A, Jakobson M, et al. Glycogen synthase kinase-3 inactivation and stabilization of beta-catenin induce nephron differentiation in isolated mouse and rat kidney mesenchymes. J Am Soc Nephrol 2007;18:1130-1139.
27. Igarashi P. Kidney-specific gene targeting. J Am Soc Nephrol 2004;15:2237-2239.
28. Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002;110: 341-350.
29. Chen S, Ge Y, Si J, et al. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int 2008;74:1128-1138.
30. Gong R, Rifai A, Dworkin LD. Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: targeting the inflamed vascular endothelium. J Am Soc Nephrol 2006;17:2464-2473.
31. Takemoto M, Asker N, Gerhardt H, et al. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 2002;161: 799-805.
32. Gomez RA, Sequeira Lopez ML, Fernandez L, et al. The maturing kidney: development and susceptibility. Ren Fail 1999;21:283-291.
33. Wu D, Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci 2010;35:161-168.
34. Yuskaitis CJ, Jope RS. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 2009;21:264-273.
35. Dugo L, Collin M, Allen DA, et al. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 2005;33:1903-1912.
36. Coryell W. Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. Bipolar Disord 2009;11(Suppl 2):77-83.
37. O'Brien WT, Klein PS. Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans 2009;37:1133-1138.
38. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002;43:1158-1164.
39. Gitlin M. Lithium and the kidney: an updated review. Drug Saf 1999;20:231-243.
40. Hetmar O, Brun C, Ladefoged J, et al. Long-term effects of lithium on the kidney: functional-morphological correlations. J Psychiatr Res 1989;23:285-297.
41. Timmer RT, Sands JM. Lithium intoxication. J Am Soc Nephrol 1999;10:666-674.
42. Smith GC, Balfe JW, Kooh SW. Anticonvulsants as a cause of Fanconi syndrome. Nephrol Dial Transplant 1995;10:543-545.
43. Jorgensen F, Larsen S, Spanager B, et al. Kidney function and quantitative histological changes in patients on long-term lithium therapy. Acta Psychiatr Scand 1984;70:455-462.